2023 was a troublesome 12 months for the biopharma sector, with quite a few organizations downsizing and restructuring their workforces to stay afloat. There are actually indications of Restoration, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences market while in the latter Component of 2023 and https://sites.google.com/view/bio-sites/blog